Evidence map›Paper›PMID 41676134›Full record

ArticleFrontiers in immunology2026

Comparable immune escape capacity for NB.1 with that of JN.1 variant and survey of infection with severe acute respiratory syndrome coronavirus 2 variants among Chinese

Youhua Yuan, Yiman Geng, Qiyuan Zhu, Bingfu Sun, Junhong Xu, Xiaohuan Mao, Xiaohuan Zhang, Wenqian Tian, Jing Zhao, Peiming Zheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Youhua YuanDepartment of Special Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Yiman Geng *Department of PCR, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Qiyuan Zhu *Department of Laboratory, Huaxian People's Hospital, Anyang, Henan, China.
Bingfu Sun *Department of Diagnosis and Treatment, Zhengzhou Municipal Fuchong Pet Hospital, Zhengzhou, Henan, China.
Junhong XuDepartment of Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Xiaohuan MaoDepartment of Special Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Xiaohuan ZhangDepartment of Special Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Wenqian TianDepartment of Special Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Jing ZhaoDepartment of PCR, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, China.
Peiming ZhengDepartment of Diagnosis and Treatment, Zhengzhou Municipal Fuchong Pet Hospital, Zhengzhou, Henan, China.
Lan GaoDepartment of Diagnosis and Treatment, Zhengzhou Municipal Fuchong Pet Hospital, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neutralising antibodies and infection with the newest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant NB.1 in Chinese Methods: A total of 392 serum samples from ill cats were subjected to enzyme-linked immunosorbent assay (ELISA) to detect the concentration of total antibodies against the receptor-binding domain of SARS-CoV-2; 40 serum samples screened positive by ELISA were subjected to pseudovirus neutralisation test to detect the titres of neutralising antibodies against the JN.1 and NB.1 variants, and 132 throat swab samples from ill cats were screened using specific reverse transcription polymerase chain reaction. Results: The geometric mean neutralising titres against the total, NB.1, and JN.1 Omicron variants were 9.51 (95% confidence interval: 7.34-12.3), 24.26 (18.84-31.23), and 48.79 (36.51-65.21) among 40 serum samples from ill cats, respectively. Therefore, neutralisation assays against JN.1 and NB.1 indicated 5.1- and 2.6-fold reductions in neutralising antibody titres, respectively, compared with the total antibody. Additionally, NB.1 showed a 2.91-fold reduction in neutralising antibody titres compared with JN.1. None of the throat swabs from the 132 ill cats were found to be infected with SARS-CoV-2 variants. Conclusions: NB.1 showed increased immune escape capacity in serum compared with JN.1 among Chinese

Indexed as

Antibodies, ViralCat DiseasesCOVID-19Immune EvasionSARS-CoV-2AnimalsAntibodies, NeutralizingCatsChinaEnzyme-Linked Immunosorbent AssayNeutralization TestsAntibodies, NeutralizingAntibodies, Viralenzyme-linked immunosorbent assayFelis silvestris catusimmune escapeJN.1NB.1pseudovirus neutralisation test

Identifiers

PMID41676134
PMCPMC12886400

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.